Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-018-27950-9
Title: Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Authors: Li, F.-F
Liu, B.-L
Yin, G.-P
Yan, R.-N
Zhang, D.-F
Wu, J.-D
Ye, L 
Su, X.-F
Ma, J.-H
Keywords: antidiabetic agent
insulin
metformin
adult
blood
blood glucose monitoring
combination drug therapy
controlled study
drug effect
female
glucose blood level
human
male
middle aged
non insulin dependent diabetes mellitus
randomized controlled trial
subcutaneous drug administration
Adult
Blood Glucose
Blood Glucose Self-Monitoring
Diabetes Mellitus, Type 2
Drug Therapy, Combination
Female
Humans
Hypoglycemic Agents
Infusions, Subcutaneous
Insulin
Male
Metformin
Middle Aged
Issue Date: 2018
Publisher: Nature Publishing Group
Citation: Li, F.-F, Liu, B.-L, Yin, G.-P, Yan, R.-N, Zhang, D.-F, Wu, J.-D, Ye, L, Su, X.-F, Ma, J.-H (2018). Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. Scientific Reports 8 (1) : 9713. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-018-27950-9
Rights: Attribution 4.0 International
Abstract: To investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations. © 2018 The Author(s).
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/178405
ISSN: 2045-2322
DOI: 10.1038/s41598-018-27950-9
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-018-27950-9.pdf1.25 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

1
checked on Feb 27, 2021

Page view(s)

30
checked on Feb 25, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons